Fresenius Medical Care North America
Health care company focused on renal and other chronic conditions
Based in DC
🤖
AI Overview
With $1.6M in lobbying spend across 29 quarterly filings, Fresenius Medical Care North America is a significant lobbying presence.
$1.6M
Total Lobbying Spend
29
Quarterly Filings
1
Lobbying Firms Used
5
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2018 | $200K |
| 2019 | $200K |
| 2020 | $200K |
| 2021 | $180K |
| 2022 | $240K |
| 2023 | $240K |
| 2024 | $180K |
| 2025 | $180K |
Lobbying Firms
AVENUE SOLUTIONS
What They Lobby For
- Issues related to healthcare discussions/offsets for budget deal and healthcare extenders; H.R. 1892 / PL 115-123, Bipartisan Budget Act of 2018; H.R. 1625 / PL 115-141, Omnibus/Consolidated Appropriations Act of 2018
- Bundled Payments for Care Improvement (BPCI) program; SNP reauthorization; Medicare extenders; S. 870, CHRONIC Care Act of 2017; Issues related to chronic kidney disease and ESRD; H.R. 3178, Medicare Part B Improvement Act of 2017; H.R. 4143/S. 2065, Dialysis PATIENTS Demonstration Act of 2017; Calcimimetics change to bundle payment
- H.R. 4143/S. 2065, Dialysis PATIENTS Demonstration Act of 2017
- Issues related to opioids policies and offsets; H.R. 6, Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT for Patients and Communities Act); S. 3120, Helping to End Addiction and Lessen Substance Use Disorders Act of 2018 (HEAL Act of 2018); S. 2680, Opioid Crisis Response Act of 2018;
- VA contracting extension
- H.R. 4143/S. 2065, Dialysis PATIENTS Demonstration Act of 2017; Vascular access reimbursement (2019 ASC Proposed Rule)
- Vascular access reimbursement (2019 ASC Proposed Rule); End-Stage Renal Disease Seamless Care Organization (ESCO) Model methodology
- Issues related to opioids policies and offsets; H.R. 6, Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT for Patients and Communities Act); S. 3120, Helping to End Addiction and Lessen Substance Use Disorders Act of 2018 (HEAL Act of 2018); S. 2680, Opioid Crisis Response Act of 2018
- Issues related to End Stage Renal Disease and Chronic Kidney Disease
- Vascular access reimbursement (2019 ASC Proposed Rule); End-Stage Renal Disease Seamless Care Organization (ESCO) Model methodology; S. 988, Improving Transparency and Accuracy in Medicare Part D Spending Act
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.